As of Q4'25, Eli Lilly (LLY) reported a diluted EPS of USD 7.39, marking the highest value in the period covered. Year-over-year EPS growth for this quarter reached 51.4%, indicating strong earnings momentum at the end of 2025. From Q1'23 to Q4'25, LLY's diluted EPS demonstrated significant volatility, with a notable dip into negative territory in Q3'23 (-0.06) followed by a robust recovery and sustained growth. The most substantial increases occurred from Q2'24 onward, with EPS rising sharply and YoY growth peaking at over 18x in Q3'24 and 4.8x in Q3'25. This trend highlights a period of accelerated earnings expansion, particularly in the latter half of the observed timeframe.